About Mink Therapeutics
Mink Therapeutics (NASDAQ:INKT) specializes in developing innovative therapies aimed at transforming the treatment landscape for patients facing serious diseases. With a focus on utilizing cutting-edge research and technology, Mink is dedicated to advancing a diverse portfolio of therapeutic candidates through clinical development. Their projects span a range of therapeutic areas, including oncology, autoimmune disorders, and infectious diseases. Mink's objective is to bring novel treatments from the bench to the bedside, addressing unmet medical needs and improving patient outcomes. The company's operations are fueled by a commitment to excellence in research and development, with an emphasis on collaboration and innovation to achieve breakthroughs in medicine.
Snapshot
Operations
Products and/or services of Mink Therapeutics
- Development of novel immunotherapies targeting hard-to-treat cancers using proprietary technology.
- Collaboration on a gene editing platform to enhance the efficacy of cancer treatments.
- Research into personalized cancer vaccines leveraging patient-specific tumor neoantigens.
- Advanced diagnostics services for early detection of oncological diseases.
- Partnership in creating monoclonal antibodies for immune system modulation in cancer therapy.
- Investment in AI-driven platforms for optimizing drug development processes.
Mink Therapeutics executive team
- Dr. Garo H. Armen Ph.D.Executive Chairman
- Dr. Jennifer S. Buell Ph.D.President, CEO & Director
- Ms. Christine M. KlaskinTreasurer and Principal Financial & Accounting Officer
- Ms. Eleni Chantzoura Ph.D.Director & Head of Discovery
- Ms. Terese C. Hammond M.D.Head of Inflammatory & Pulmonary Diseases